註冊並分享邀請連結,可獲得影片播放與邀請獎勵。

METANOVA LABS
@metanova_labs
AI drug discovery company developing agency therapeutics and the tools to find them. Powered by NOVA, open non-stop competitions #Bittensor# Subnet 68
加入 November 2024
451 正在關注    4.6K 粉絲
NOVA: Emission Split Update for Data Generation Fund Owner 26% / Miners 33% / Validators 41% With the launch of eTAO, subnet owners can now adjust how emissions are distributed. NOVA will be updating its split to allocate more resources toward what we believe is the highest-impact investment we can make in the subnet's future: experimental data generation. Wet lab data is the best investment we can make both to prove out what the subnet produces and to increase the value of what gets built on top of it. Data is the bottleneck AI-driven drug discovery faces a fundamental constraint: the quality of our predictions is ultimately limited by the experimental data available to train and validate them. Much of today's publicly available drug discovery data is fragmented across studies, generated using different experimental protocols, and inconsistent in quality and coverage. Generating high-quality experimental data allows us to address that limitation directly. It gives miners better ground truth for model development, provides independent validation of their predictions, and helps us identify which approaches actually translate into experimental success. The industry is making the same bet. Some of the largest investments in AI-driven biology are now directed toward generating the experimental data necessary to train and validate better models. Biohub committed $400M of a $500M, five-year initiative to data generation, infrastructure and measurement technology, and later expanded into a $1.8B effort backed by Meta, Google DeepMind and Isomorphic Labs, who collectively committed $300M. The OpenAI Foundation gave $15M to OpenADMET to generate public ADME datasets, which will be used in prospective blind challenges against newly measured experimental data. Octant continues the high-throughput data generation behind it. Leash Bio used a $9.3M seed round to scale data collection for a foundational medicinal chemistry model, producing a dataset that screened 133 million molecules against each protein. Anthropic has set up a physical biology lab in the Bay Area. What the additional funds will support The additional owner allocation will go into a dedicated R&D fund for wet lab data generation. 1. ADME model training competition. The first use of the fund is generating the experimental data behind our ADME competition, currently in design and development. High-quality, standardized ADME data is what turns a competition from a benchmark into something that produces models with real predictive value. 2. Advancing assets under development. Where it makes sense, the fund can also support experimental work that moves our in-development assets forward. Why this benefits the entire NOVA ecosystem We believe generating experimental data is one of the most effective ways to increase the long-term value of the subnet. For miners, better datasets and scientifically grounded evaluations create opportunities to develop more capable models, compete on meaningful performance improvements, and contribute work with greater real-world utility. For validators, stronger experimental benchmarks improve the ability to assess model quality and reward useful contributions. For tokenholders, better models, experimentally validated discoveries, and progress toward valuable therapeutic assets can strengthen NOVA's competitive position and long-term commercial potential. The economic opportunity extends beyond any individual competition. We are building an increasingly capable scientific discovery platform, and the data generated through our R&D efforts can become a compounding asset for the entire ecosystem. Miner incentives remain strong Miners will still receive a meaningfully larger share than the owner (33% vs. 26%), and we believe the rewards will preserve healthy, competitive incentives for participation. Better data and better-validated competitions also make the work miners do more valuable over time. Protecting token health Funds from the R&D allocation will be converted to cover lab costs gradually, distributed over time rather than sold in size, to limit market impact and preserve token health. The bottom line We think this is the single best thing we can do to accelerate our progress, increase our chance of success, and create value for everyone with a stake in NOVA, including miners, validators, and tokenholders. It is time for us to scale real-world validation.
顯示更多